ASA404: update on drug development
- PMID: 18808313
- DOI: 10.1517/13543784.17.10.1547
ASA404: update on drug development
Abstract
Background: Interrupting tumour blood flow and delivery of nutrients to cause tumour death is the aim of antiangiogenic and vascular disrupting agents (VDAs). ASA404 is the first VDA to enter Phase III trials.
Objective: We review the preclinical and clinical data on this interesting agent and consider its place in modern therapeutics.
Methods: PubMed database was searched for 'ASA404', 'AS1404', 'DMXAA', 'vascular disrupting agents', 'ASA404 clinical trials', 'AS1404 clinical trials', 'DMXAA clinical trials'.
Results/conclusions: ASA404 is a tumour VDA that is well tolerated and has shown promise in the treatment of NSCLC in combination with paclitaxel and carboplatin. A confirmatory Phase III trial is currently ongoing.
Similar articles
-
The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.Expert Opin Investig Drugs. 2010 Feb;19(2):295-304. doi: 10.1517/13543780903540214. Expert Opin Investig Drugs. 2010. PMID: 20050824
-
Temporal aspects of the action of ASA404 (vadimezan; DMXAA).Expert Opin Investig Drugs. 2010 Nov;19(11):1413-25. doi: 10.1517/13543784.2010.529128. Expert Opin Investig Drugs. 2010. PMID: 20964495 Free PMC article. Review.
-
Cardiovascular toxicity profiles of vascular-disrupting agents.Oncologist. 2011;16(8):1120-30. doi: 10.1634/theoncologist.2010-0432. Epub 2011 Jul 8. Oncologist. 2011. PMID: 21742963 Free PMC article.
-
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.J Clin Oncol. 2011 Aug 1;29(22):2965-71. doi: 10.1200/JCO.2011.35.0660. Epub 2011 Jun 27. J Clin Oncol. 2011. PMID: 21709202 Clinical Trial.
-
Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.Cancer. 2010 Apr 15;116(8):1859-71. doi: 10.1002/cncr.24975. Cancer. 2010. PMID: 20166210 Review.
Cited by
-
Carboxyxanthones: Bioactive Agents and Molecular Scaffold for Synthesis of Analogues and Derivatives.Molecules. 2019 Jan 5;24(1):180. doi: 10.3390/molecules24010180. Molecules. 2019. PMID: 30621303 Free PMC article. Review.
-
Synthetic Chiral Derivatives of Xanthones: Biological Activities and Enantioselectivity Studies.Molecules. 2019 Feb 22;24(4):791. doi: 10.3390/molecules24040791. Molecules. 2019. PMID: 30813236 Free PMC article. Review.
-
The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts.BMC Cancer. 2012 Jun 13;12:242. doi: 10.1186/1471-2407-12-242. BMC Cancer. 2012. PMID: 22695475 Free PMC article.
-
MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-acetic acid in gliomas.J Cereb Blood Flow Metab. 2009 Aug;29(8):1373-82. doi: 10.1038/jcbfm.2009.68. Epub 2009 May 20. J Cereb Blood Flow Metab. 2009. PMID: 19458603 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
